Publicacións en colaboración con investigadores/as de Pfizer (United States) (69)

2024

  1. A translational framework to DELIVER nanomedicines to the clinic

    Nature Nanotechnology

  2. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

  3. Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain

    Infectious Diseases and Therapy, Vol. 13, Núm. 6, pp. 1315-1331

  4. Genome-wide Association Study of Susceptibility to Respiratory Syncytial Virus Hospitalization in Young Children <5 Years of age

    Journal of Infectious Diseases, Vol. 230, Núm. 2, pp. e333-e341

  5. Whole exome sequencing identifies new susceptibility candidates underlying community-acquired pneumonia

    Genes and Diseases, Vol. 11, Núm. 6

2023

  1. Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 23, Núm. 10, pp. 1139-1146

  2. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 3, pp. 331-343

  3. Meningococcal Disease in the Post–COVID-19 Era: A Time to Prepare

    Infectious Diseases and Therapy

2022

  1. Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 3, pp. 156-165

  2. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

    Journal of Infectious Diseases, Vol. 226, pp. S29-S37

  3. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  4. Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

    Journal of Infectious Diseases, Vol. 226, pp. S135-S141

  5. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

  6. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

    Journal of Infectious Diseases, Vol. 226, pp. S130-S134

  7. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

    Journal of Clinical Epidemiology, Vol. 147, pp. 11-20

2021

  1. Cappric study—characterization of community-acquired pneumonia in spanish adults managed in primary care settings

    Microorganisms, Vol. 9, Núm. 3, pp. 1-11

  2. Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 773-780

  3. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus

    Nature Communications, Vol. 12, Núm. 1

  4. Global and regional burden of hospital admissions for pneumonia in older adults: A systematic review and meta-analysis

    Journal of Infectious Diseases, Vol. 222, pp. S570-S576

  5. Immunological and inflammatory biomarkers of susceptibility and severity in adult respiratory syncytial virus infections

    Journal of Infectious Diseases, Vol. 222, pp. S584-S591